Ruben Mesa/LinkedIn
Aug 31, 2026, 14:28
Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
Ruben Mesa, President of Cancer National Service Line at Advocate Health, shared a post on LinkedIn:
“Honored to have been involved with (as PI of the Global Surpass ET trial) the now FDA approval of ROPEG INF a2b for patients with Essential Thrombocythemia.
This is the first approval in over 30 years for patients with this myeloid neoplasm MPN and helps decrease disease associated risks, symptoms, and modifies the underlying clone.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question